title: Cinacalcet in pediatric and adolescent chronic kidney disease: a single-center experience.
abstract: Cinacalcet, a calcimimetic drug, has been shown to be efficacious in adult chronic kidney disease (CKD) patients; however, it was not fully studied in pediatric CKD patients. We aimed at assessing the effect of cinacalcet on intact parathyroid hormone (iPTH) secretion in children with CKD-4/5 with iPTH consistently ≥ 300 pg/mL refractory to conventional treatment. This is a prospective cohort analysis of 28 children with uncontrolled hyper-parathyroidism secondary to stage 4 and 5 CKD admitted to a tertiary center during the period from April 2012 to April 2014. Twenty-eight patients with CKD-4/5 were assessed prospectively regarding bone biochemistry, renal ultrasonography, serum iPTH level, and medications. Patients were classified into 3 groups: group 1, 6 patients with CKD-4 on supplemental and supportive therapy; group 2, 6 patients with CKD-5 on hemodialysis and; group 3, 16 patients with CKD-5 on automated peritoneal dialysis. Patients were between the ages of 9 months and 18 years on commencing cinacalcet at doses of 0.5 to 1.5 mg/kg. All patients showed at least a 60% reduction in iPTH (60%-97%). Highly significant reduction in iPTH and serum alkaline phosphatase levels was detected post-cinacalcet. The serum calcium (Ca), phosphate (P), and Ca × P product were unaffected. Treatment was well tolerated with no hypophosphatemia, hypocalcemia, or other adverse effects almost in all patients. Cinacalcet use was proven safe for all pediatric and adolescent patients with CKD-4/5 during the study period, and at the same time most of the patients reached the suggested iPTH target values.
authors.affiliation: From the Faculty of Medicine, Taif University, Al Hada Armed Forces Hospital, Taif, KSA (AAA); Faculty of Medicine, Cairo University, Cairo, Egypt, Al Hada Armed Forces Hospital, Taif, KSA (NMK); Al Hada Armed Forces Hospital, Taif, KSA (MWA); and Faculty of Medicine, Zagazig University, Egypt (LMS).
authors.forename: Abdulla A
authors.initials: AA
authors.lastname: Alharthi
authors.forename: Naglaa M
authors.initials: NM
authors.lastname: Kamal
authors.forename: Mohamed W
authors.initials: MW
authors.lastname: Abukhatwah
authors.forename: Laila M
authors.initials: LM
authors.lastname: Sherief
mesh_terms: D000293:Adolescent; D000469:Alkaline Phosphatase / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D057966:Calcimimetic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D000069449:Cinacalcet; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007223:Infant; D007668:Kidney / Q000000981:diagnostic imaging / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D009281:Naphthalenes / Q000008:administration & dosage / Q000009:adverse effects; D010281:Parathyroid Hormone / Q000378:metabolism; D062072:Patient Acuity; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D006435:Renal Dialysis / Q000379:methods; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D012529:Saudi Arabia; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D057966:Calcimimetic Agents; D009281:Naphthalenes; D010281:Parathyroid Hormone; D000469:Alkaline Phosphatase; D000069449:Cinacalcet